Browsing: GLP1s

An oral small molecule that increases energy expenditure rather than suppressing appetite produced substantial weight loss while preserving lean mass in mouse models of obesity, suggesting a potentially complementary strategy to GLP-1–based therapies

For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10 to 15% or more. Despite their success, however, scientists have not fully understood how these drugs work in the brain

As GLP-1 medications transform obesity care, researchers are testing new hormone combinations aimed at improving weight loss, tolerability, and long-term outcomes.

Glucagon-like peptide 1 (GLP-1) receptor agonist drugs have been on the forefront as a promising treatment for multiple health issues — specifically in the management of type 2 diabetes and weight management

Nestlé has announced plans to develop products specifically aimed at GLP-1 users

SmartBrief editor Tom Parks reported on presentations at the American Association of Nurse Practitioners National Conference that focused on weight loss, obesity and new GLP-1 medications. This story covers those topics and also has a follow-up: Food noise and how to turn down the volume

1 meds—perhaps better known by brand names like Ozempic and Wegovy—have become widespread as weight loss tools. But there’s evidence that links their use to to a range of positive health outcomes, and now researchers say they may “alter social and economic outcomes” too

GLP-1s aren’t the problem, depending on them is – Castanet.net Kelowna’s Homepage Saturday, Aug 15 ObitsAutoMallEventsCamsTango

Popular semaglutide weight-loss drugs such as Ozempic and Wegovy may work in a more complex way than we realized

A new study suggests that using GLP-1 medications, such as Ozempic and Wegovy, before bariatric surgery may not lead to greater weight loss after the procedure